Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Model Overview

YW Yingcheng Wang
MR Mingjun Rui
LY Lan Yang
XW Xintian Wang
YS Ye Shang
AM Aixia Ma
HL Hongchao Li
ask Ask a question
Favorite

A PS model with three mutually exclusive health states was developed to estimate the costs and outcomes of the first-line treatment of patients with extensive-stage SCLC in Microsoft Excel (Figure 1). The proportion of patients in the postprogression (PP) state in each cycle was calculated as the difference between OS and PFS based on data from the IMpower133 trial. Each cycle lasted 3 weeks, which was consistent with the IMpower133 trial. A lifetime horizon (2.5 years) was chosen, and ≥95% of patients in the control group died. We examined the following outcomes: quality-adjusted life-years (QALYs), life-years gained (LYGs), and costs. All of them were discounted by 3%. The US payer perspective was taken; therefore, only the direct medical care costs were included.

Model structure.

Copyright and License information:  ©2021 Wang, Rui, Yang, Wang, Shang, Ma and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A